GLP-1 Shift: Employers Drop Coverage as Grocery Spending Drops $1B

Your employer might soon stop paying for your weight loss injections. As GLP-1 drugs surge in popularity, a growing number of companies are reconsidering coverage, while grocery bills are shrinking by billions.

The Science

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) mimic a natural hormone that regulates appetite and blood sugar. By slowing gastric emptying and acting on brain centers, they reduce cravings and caloric intake. A study by Worldpanel by Numerator in the UK found that households with at least one GLP-1 user bought 299 million fewer food items in the year after starting the medication, particularly chocolate and potato chips. Use of these drugs has nearly tripled in two years: 6.3% of UK households had at least one current user in 2026, up from 4.1% in 2025 and 2.3% in 2024. This explosive growth reflects not only the efficacy of these medications but also a cultural shift in how obesity is perceived—as a chronic condition requiring medical intervention rather than a lifestyle failure. However, the rapid adoption raises concerns about long-term sustainability and unknown side effects, especially given the relatively short follow-up in clinical trials.

“The GLP-1 boom is reshaping employer benefits, patient access, and the food industry simultaneously.”

Key Findings

• Employer coverage at risk: 10% of large employers currently covering GLP-1s for weight loss plan to drop coverage in 2027, per the Business Group on Health. A Mercer survey found 5% of companies with over 500 employees also plan to drop coverage. This trend could accelerate if drug prices remain high; annual costs per patient can exceed $10,000.
• Current coverage rates: 67% of large employers cover GLP-1s in 2026 (Business Group on Health), while 44% of companies with 500+ employees cover them (Mercer). Despite coverage, many employees face high copays or prior authorization requirements that limit access.
• Grocery spending impact: GLP-1 use in the UK has wiped approximately $1 billion off annual grocery spending, according to Bloomberg News. This represents a 2-3% drop in categories like snacks and sweets, prompting major retailers like Tesco and Sainsbury's to adjust their inventory strategies.
• Reduced food purchases: Households with GLP-1 users bought 299 million fewer items, with significant drops in snacks and treats. Worldpanel data show chocolate purchases fell 15% and potato chips 12% in these households.
• Explosive growth: UK household penetration of GLP-1s rose from 2.3% in 2024 to 6.3% in 2026. If the trend continues, projections suggest one in ten households could have a user by 2028.

Why It Matters

This shift has profound implications. For patients, losing coverage could mean out-of-pocket costs of hundreds of dollars per month, making treatment inaccessible. Already, socioeconomic disparities are widening: in the UK, GLP-1 use is three times higher in high-income households than low-income ones, according to Worldpanel data. For employers, it's a cost-benefit calculation: covering these drugs can improve employee health and productivity but at a high upfront cost. A Mercer analysis suggests that covering GLP-1s for a company with 10,000 employees could cost over $5 million annually, straining health budgets. Meanwhile, the food industry faces a demand shock as millions of users cut back on snacks, potentially accelerating reformulation toward healthier options. Nestlé and Unilever have already announced low-calorie, high-protein product lines targeting GLP-1 users.

From a public health perspective, reduced snack consumption could lower obesity rates and related diseases. However, unequal access may widen health disparities, as those who can afford out-of-pocket costs reap the benefits while others are left behind. Additionally, treatment discontinuation is common: a study in JAMA Network Open found that 40% of users stop the medication within the first year, often due to side effects or cost, leading to significant weight regain.

Your Protocol

If you're considering or currently using GLP-1s for weight loss, here's how to navigate the changing landscape:

1. 1Check your coverage now: Review your health plan annually. Ask your employer if changes are planned for 2027. If coverage is dropped, explore patient assistance programs (e.g., from Novo Nordisk) or savings cards from manufacturers. Also consider individual marketplace plans that may offer coverage.
2. 2Optimize nutrition during treatment: Use the reduced cravings to build healthy habits. Focus on protein (1.6-2.2 g/kg body weight) to preserve muscle mass, and incorporate fiber-rich vegetables. Avoid ultra-processed foods even when appetite returns. A study from the University of Leeds suggests that users who combine GLP-1s with nutritional counseling lose 20% more weight than those on medication alone.
3. 3Plan for long-term maintenance: GLP-1s are often needed long-term to maintain weight loss. Discuss a tapering strategy with your doctor if you plan to stop. Combine with strength training (2-3 times per week) and a structured diet to prevent regain. Monitor for side effects like nausea or muscle loss, and get regular check-ups for pancreatic and thyroid function, as rare cases of pancreatitis and thyroid cancer have been reported.

What To Watch Next

Watch for upcoming studies on oral GLP-1 formulations, which could lower costs and improve adherence. Also monitor employer coalitions like the Business Group on Health for updated coverage trends. Finally, keep an eye on the UK grocery data: if the trend continues, food companies may pivot toward healthier product lines, potentially benefiting all consumers. Additionally, research on long-term cardiovascular outcomes and the impact of GLP-1s on conditions like fatty liver disease will shape future guidelines.

The Bottom Line

GLP-1 drugs are revolutionizing weight management, but their future depends on affordability and employer decisions. If you're using them, secure your access and double down on nutrition and exercise. The data show these drugs change behavior at scale—use that window to build lasting habits. The next few years will determine whether GLP-1s become a standard wellness tool or a luxury for the few.